ATE365206T1 - Verfahren zur entwicklung von einem hiv impfstoff - Google Patents

Verfahren zur entwicklung von einem hiv impfstoff

Info

Publication number
ATE365206T1
ATE365206T1 AT99932507T AT99932507T ATE365206T1 AT E365206 T1 ATE365206 T1 AT E365206T1 AT 99932507 T AT99932507 T AT 99932507T AT 99932507 T AT99932507 T AT 99932507T AT E365206 T1 ATE365206 T1 AT E365206T1
Authority
AT
Austria
Prior art keywords
hiv
immune response
developing
hiv vaccine
inactivated
Prior art date
Application number
AT99932507T
Other languages
English (en)
Inventor
Adan Rios
Original Assignee
Adan Rios
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adan Rios filed Critical Adan Rios
Application granted granted Critical
Publication of ATE365206T1 publication Critical patent/ATE365206T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99932507T 1998-02-13 1999-02-12 Verfahren zur entwicklung von einem hiv impfstoff ATE365206T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7464698P 1998-02-13 1998-02-13

Publications (1)

Publication Number Publication Date
ATE365206T1 true ATE365206T1 (de) 2007-07-15

Family

ID=22120781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99932507T ATE365206T1 (de) 1998-02-13 1999-02-12 Verfahren zur entwicklung von einem hiv impfstoff

Country Status (7)

Country Link
US (2) US6383806B1 (de)
EP (1) EP1056838B1 (de)
AT (1) ATE365206T1 (de)
AU (1) AU764938B2 (de)
CA (1) CA2323011C (de)
DE (1) DE69936337T2 (de)
WO (1) WO1999041360A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232494B1 (en) 1998-02-12 2001-05-15 Monsanto Company Process for the preparation of N-(phosphonomethyl)glycine by oxidizing N-substituted N-(phosphonomethyl)glycine
US6503753B1 (en) * 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US9974847B2 (en) * 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
CA2439188A1 (en) * 2001-02-27 2002-09-19 Institut Pasteur Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro
US20050112139A1 (en) 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
US8613934B2 (en) 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
WO2005093049A1 (en) * 2004-03-22 2005-10-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Cellular and viral inactivation
KR100568542B1 (ko) * 2004-08-19 2006-04-07 삼성전자주식회사 자기 램 소자의 기록방법
CA2582426A1 (en) * 2004-10-04 2006-04-13 Biovaxim Limited Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005769A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US8367315B2 (en) * 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
US9610248B2 (en) 2010-07-06 2017-04-04 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (de) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Verfahren und zusammensetzungen für therapeutika

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
US5861282A (en) 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
US5866137A (en) 1990-10-12 1999-02-02 Benjamin Rovinski Self-assembled, non-infectious, non-replicating; immunogenic retrovirus-like particles comprising modified HIV genomes devoid of long terminal repeats and chimeric envelope glycoproteins
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles

Also Published As

Publication number Publication date
AU3293799A (en) 1999-08-30
US20030129200A1 (en) 2003-07-10
US6653130B2 (en) 2003-11-25
DE69936337T2 (de) 2008-02-21
EP1056838B1 (de) 2007-06-20
CA2323011A1 (en) 1999-08-19
AU764938B2 (en) 2003-09-04
WO1999041360A1 (en) 1999-08-19
DE69936337D1 (de) 2007-08-02
CA2323011C (en) 2013-01-15
EP1056838A1 (de) 2000-12-06
US6383806B1 (en) 2002-05-07

Similar Documents

Publication Publication Date Title
DE69936337D1 (de) Verfahren zur entwicklung von einem hiv impfstoff
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
PT1294893E (pt) Modificacao do antigenio nuclear de hepatite b
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
ATE501726T1 (de) Zusammensetzung mit immunogenen mikroteilchen
DK0726758T3 (da) Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus
ATE426412T1 (de) Adjuvante influenza-vakzine
ES2091777T3 (es) Procedimiento para preparar un ensayo inmunologico de transferencia western.
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
EP0687182A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
ATE401392T1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
ITMI913092A0 (it) Vaccino di poxvirus ricombinate del virus del morbillo
DE69533067D1 (de) Hepatis e-virus antigene und dessen verwendungen
CO5280138A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para en vacas gestantes
DE60231821D1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
ATE278795T1 (de) Herpesviren für die modulation einer immunantwort
AU5573196A (en) A pluripotent vaccine against enveloped viruses
DK172633B1 (da) Fremgangsmåde til fremstilling af en FeLV-vaccine og sammensætning og vaccine omfattende en således fremstillet inaktiveret
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
DE68920345D1 (de) Lebendes Kombinationsvakzin.
SE9202934D0 (sv) Vacciner mot melanom
WO2003054176A3 (en) Preparation of vaccines using photosensitizer and light

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties